triazoles has been researched along with ciclopirox in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 12 (70.59) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Cruz Talonia, F; García Figueroa, RG; Ramírez Palacios, D; Romero Cabello, R; Sauceda, L | 1 |
| Czaika, V; Schmalreck, A; Schultze, W; Sterry, W; Tietz, HJ | 1 |
| Sellart-Altisent, M; Torres-Rodríguez, JM | 1 |
| Ghannoum, MA; Mukherjee, PK; Shehata, AS | 1 |
| Vera-Cabrera, L; Welsh, E; Welsh, O | 1 |
| Al-awar, R; Alizadeh, S; Aman, A; Attisano, L; Bao, RY; Chau, A; Christova, T; Gronda, M; Hogge, DE; Hurren, R; Isaac, M; Jitkova, Y; Joseph, B; Kasper, J; Miller, BW; Perusini, S; Schimmer, AD; Song, S; Subramaniam, R; Weir, SJ; Wrana, JL | 1 |
| Lipner, S; Scher, RK | 1 |
| Hossin, B; Murdan, S; Rizi, K | 1 |
| Rosen, T; Stein Gold, LF | 3 |
| Chanda, S; Coronado, D; Del Rosso, J; Zane, LT | 1 |
| Adigun, CG; Gellings Lowe, N; Hall, SB; Joseph, WS; Rich, P; Vlahovic, TC; Zane, LT | 1 |
| Lipner, SR; Scher, RK | 1 |
| Ko, D; Lipner, SR | 1 |
| Burgalassi, S; Celandroni, F; Ghelardi, E; Mazzantini, D; Monti, D; Tampucci, S; Vecchione, A | 1 |
| Lipner, SR; Wang, Y | 1 |
3 review(s) available for triazoles and ciclopirox
| Article | Year |
|---|---|
Onychomycosis.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Ciclopirox; Drug Administration Schedule; Drug Therapy, Combination; Fluconazole; Foot Dermatoses; Humans; Itraconazole; Mitosporic Fungi; Morpholines; Naphthalenes; Onychomycosis; Pyridones; Pyrimidines; Terbinafine; Thiazoles; Triazoles; Voriconazole | 2010 |
Antifungal agents for onychomycosis: new treatment strategies to improve safety.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Chemical and Drug Induced Liver Injury; Ciclopirox; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Itraconazole; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Triazoles | 2016 |
Onychomycosis: Treatment and prevention of recurrence.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Fluconazole; Humans; Itraconazole; Laser Therapy; Nanoparticles; Onychomycosis; Photochemotherapy; Plasma Gases; Prognosis; Pulse Therapy, Drug; Risk Factors; Secondary Prevention; Severity of Illness Index; Terbinafine; Triazoles | 2019 |
2 trial(s) available for triazoles and ciclopirox
| Article | Year |
|---|---|
[Effectiveness and safety of ciclopirox olamine 1% vaginal cream versus terconazole 0.8% vaginal cream in the treatment of genital candidiasis].
Topics: Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Ciclopirox; Female; Humans; Pyridones; Triazoles; Vaginal Creams, Foams, and Jellies | 2000 |
Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.
Topics: Acute Disease; Administration, Oral; Benzoates; beta Catenin; Cell Line, Tumor; Cell Proliferation; Ciclopirox; Colorectal Neoplasms; Deferasirox; Deferoxamine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hydrazones; Iron; Iron Chelating Agents; Leukemia, Myeloid; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Pyridones; Reverse Transcriptase Polymerase Chain Reaction; Triazoles; Wnt Proteins; Wnt Signaling Pathway | 2011 |
12 other study(ies) available for triazoles and ciclopirox
| Article | Year |
|---|---|
[Antifungal susceptibility testing in chronically recurrent vaginal candidosis as basis for effective therapy].
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Chronic Disease; Ciclopirox; Female; Fluconazole; Flucytosine; Humans; Itraconazole; Microbial Sensitivity Tests; Naphthalenes; Pyridones; Pyrimidines; Terbinafine; Triazoles; Vaginitis; Voriconazole | 2000 |
[Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani].
Topics: Antifungal Agents; Cellulitis; Ciclopirox; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Resistance, Multiple, Fungal; Foot Dermatoses; Fusarium; Humans; Imidazoles; Immunocompetence; Itraconazole; Male; Middle Aged; Mozambique; Onychomycosis; Pyridones; Pyrimidines; Recurrence; Toes; Travel; Triazoles; Urea; Voriconazole | 2006 |
Comparison between the standardized clinical and laboratory standards institute M38-A2 method and a 2,3-Bis(2-Methoxy-4-Nitro-5-[(Sulphenylamino)Carbonyl]-2H-tetrazolium hydroxide- based method for testing antifungal susceptibility of dermatophytes.
Topics: Antifungal Agents; Arthrodermataceae; Ciclopirox; Humans; Indicators and Reagents; Microbial Sensitivity Tests; Microbial Viability; Mycology; Naphthalenes; Pyridones; Pyrimidines; Sensitivity and Specificity; Spectrophotometry; Terbinafine; Tetrazolium Salts; Triazoles; Vitamin K 3; Voriconazole | 2008 |
Onychomycosis: current and future therapies.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Debridement; Foot Dermatoses; Hand Dermatoses; Humans; Laser Therapy; Morpholines; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Triazoles | 2014 |
Application of Hansen Solubility Parameters to predict drug-nail interactions, which can assist the design of nail medicines.
Topics: Adolescent; Adult; Antifungal Agents; Ciclopirox; Drug Interactions; Female; Humans; Keratins; Male; Middle Aged; Morpholines; Nail Diseases; Nails; Naphthalenes; Onychomycosis; Pharmaceutical Preparations; Pyridones; Solubility; Terbinafine; Triazoles; Young Adult | 2016 |
Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Fluconazole; Foot Dermatoses; Humans; Itraconazole; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Treatment Outcome; Triazoles; United States | 2016 |
Introduction.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Foot Dermatoses; Humans; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Treatment Outcome; Triazoles | 2016 |
Using Topical Antifungal Medications: Instructions for patients.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Drug Administration Schedule; Foot Dermatoses; Humans; Onychomycosis; Pyridones; Triazoles | 2016 |
Clinical trial designs for topical antifungal treatments of onychomycosis and implications on clinical practice.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Clinical Trials, Phase III as Topic; Drug Approval; Humans; Onychomycosis; Pyridones; Research Design; Treatment Outcome; Triazoles; United States | 2017 |
Optimizing topical therapy for onychomycosis: the importance of patient education.
Topics: Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Humans; Medication Adherence; Onychomycosis; Patient Education as Topic; Triazoles | 2018 |
Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum.
Topics: Animals; Antifungal Agents; Biological Transport; Cattle; Ciclopirox; Drug Resistance, Fungal; Hoof and Claw; Humans; Keratins; Microbial Sensitivity Tests; Microtomy; Models, Biological; Mutation; Nails; Permeability; Protein Binding; Tinea; Triazoles; Trichophyton | 2019 |
Retrospective analysis of adverse events with topical onychomycosis medications reported to the United States Food and Drug Administration.
Topics: Administration, Topical; Adverse Drug Reaction Reporting Systems; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Erythema; Humans; Nails; Onychomycosis; Pigmentation; Retrospective Studies; Solutions; Treatment Failure; Triazoles; United States; United States Food and Drug Administration | 2020 |